We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investigation of Plasminogen Activator Inhibitor-1 ( PAI-1) 4G/5G promoter polymorphism in Indian venous thrombosis patients: A case-control study.
- Authors
Prabhudesai, Aniket; Shetty, Shrimati; Ghosh, Kanjaksha; Kulkarni, Bipin
- Abstract
Background The role of PAI-1 4G/5G polymorphism in venous thrombosis has been contradictory. PAI-1 4G/4G genotype is associated with elevated levels of PAI-1 resulting in a hypofibrinolytic state and a higher thrombotic risk. Objective In this study, the distribution of genotypes and frequency of alleles of the 4G/5G polymorphism of PAI-1 gene in Indian patients with different types of venous thrombosis was investigated for its role in development of thrombosis. Method A total of 87 portal vein thrombosis ( PVT), 71 Budd-Chiari syndrome ( BCS), 156 cerebral vein thrombosis ( CVT), and 163 deep vein thrombosis ( DVT) patients were studied alongside 251 healthy controls for the PAI-1 4G/5G polymorphism by allele-specific PCR. Results Frequency of 4G/4G genotype was higher in all groups in comparison with controls. 4G/4G was associated with PVT risk ( OR=2.51, 95% CI=1.29-4.96, P=.0075), BCS risk ( OR=5.98, 95% CI=2.68-13.42, P <.0001), and DVT risk ( OR=1.75, 95% CI=0.98-3.02, P=.0225). This is the first case-control study from India establishing PAI-1 4G/4G as a strong risk factor for abdominal thrombosis ( PVT and BCS). Statistically significant association was not found between 4G/4G genotype and CVT risk. Conclusion PAI-1 4G/4G is a strong risk factor for venous thrombosis in Indian patients and should be included in laboratory testing panel of thrombophilia.
- Subjects
PLASMINOGEN activator inhibitors; SERPINS; GENETIC polymorphisms; VENOUS thrombosis treatment; THROMBOSIS; PATIENTS
- Publication
European Journal of Haematology, 2017, Vol 99, Issue 3, p249
- ISSN
0902-4441
- Publication type
Article
- DOI
10.1111/ejh.12912